Further, βTRCP is shown to stimulate vascular endothelial growth factor receptor 2 (VEGFR2) ubiquitination and degradation, which inhibit angiogenesis and migration of papillary thyroid cancer cells [53]. Here, KDR is linked to thyroid gland papillary carcinoma.